• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aura Biosciences Inc.

    5/19/26 4:31:20 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AURA alert in real time by email
    S-8 1 d118275ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 19, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    AURA BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   32-0271970

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    80 Guest Street

    Boston, MA 02135

    (617) 500-8864

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

    Restricted Stock Unit Award Agreement (Inducement Award)

    Non-Qualified Stock Option Agreement (Inducement Award)

    Performance-Based Restricted Stock Unit Award Agreement (Inducement Award)

    (Full title of the plans)

     

     

    Natalie Holles

    Chief Executive Officer and President

    Aura Biosciences, Inc.

    80 Guest Street

    Boston, MA 02135

    (617) 500-8864

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Stuart Cable, Esq.

    Danielle Lauzon, Esq.

    Stephanie A. Richards, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers shares of common stock, $0.00001 par value per share (the “Common Stock”), of Aura Biosciences, Inc. (the “Registrant”) issuable pursuant to the inducement awards, as described below. As a material inducement to one newly-hired employee to accept employment with the Registrant, the Registrant granted the following equity awards to such individual (the “Inducement Awards”) on the date detailed below:

     

      •  

    Restricted stock unit awards with respect to 600,118 shares of Common Stock granted to one newly-hired employee on May 19, 2026;

     

      •  

    Stock options to purchase 2,169,103 shares of Common Stock granted to one newly-hired employee on May 19, 2026; and

     

      •  

    Performance-based restricted stock unit award with respect to 553,844 shares of Common Stock granted to one newly-hired employee on May 19, 2026.

    Each Inducement Award was approved by the Registrant’s Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the Registrant’s Amended and Restated 2021 Stock Option and Incentive Plan, and its predecessor plans.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to persons to whom the Inducement Awards have been granted as required by Rule 428(b)(1) under the Securities Act.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”), are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026;

    (b) The information specifically incorporated by reference into the Annual Report on Form 10-K for the year ended December 31, 2025 from the definitive proxy statement on Schedule 14a (other than information furnished rather than filed) filed with the Commission on April  20, 2026;

    (c) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Commission on May 11, 2026;

    (d) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on October 26, 2021, including any other amendments or reports filed for the purpose of updating such description, including  Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026; and

    (e) All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item  4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law, or DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.


    The Registrant’s certificate of incorporation and bylaws limit or eliminate the personal liability of the Registrant’s directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to the Registrant or its stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

     

      •  

    any breach of the director’s duty of loyalty to the Registrant or its stockholders;

     

      •  

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

      •  

    any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

     

      •  

    any transaction from which the director derived an improper personal benefit.

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

    In addition, the Registrant’s bylaws provide that:

     

      •  

    the Registrant will indemnify its directors, officers and, in the discretion of the Registrant’s board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

     

      •  

    the Registrant will advance reasonable expenses, including attorneys’ fees, to its directors and, in the discretion of the Registrant’s board of directors, to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the Registrant, subject to limited exceptions.

    The Registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify each of its directors, its executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. The Registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and the Registrant will indemnify its directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Registrant or in furtherance of the Registrant’s rights. Additionally, certain of the Registrant’s directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, the Registrant has agreed in the indemnification agreements that the Registrant’s obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

    The Registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    Item 8. Exhibits.

    EXHIBIT INDEX

     

    Exhibit
    No.
      

    Description

      4.1    Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156), filed with the Securities and Exchange Commission on October 25, 2021). 
      4.2    Tenth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect, as amended by the Certificate of Amendment, dated June 20, 2024 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed with the Securities and Exchange Commission on August 8, 2024). 
      4.3    Amended and Restated Bylaws of the Registrant, as currently in effect (Incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40971) filed with the Securities and Exchange Commission on March 23, 2022). 
      4.4    Fifth Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-260156) filed with the Securities and Exchange Commission on October 8, 2021). 
      4.5    Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025).
      4.6    Form of Common Stock Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025).
      4.7    Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 5, 2026.
      5.1*    Opinion of Goodwin Procter LLP.
     23.1*    Consent of Ernst & Young, Independent Registered Public Accounting Firm. 
     23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1). 
     24.1*    Power of Attorney (included on signature page). 
     99.1*#    Form of Restricted Stock Unit Award Agreement (Inducement Award)
     99.2*#    Form of Non-Qualified Stock Option Agreement (Inducement Award)
     99.3*#    Form of Performance-Based Restricted Stock Unit Award Agreement (Inducement Award)
    107*    Filing Fee Table
     
    *

    Filed herewith.

    #

    Denotes management contract or compensatory plan or arrangement.

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:


    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 19th day of May, 2026.

     

    AURA BIOSCIENCES, INC.
    By:   /s/ Natalie Holles
      Name: Natalie Holles
      Title: Chief Executive Officer and President

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Natalie Holles, Anthony Gibney and Amy Elazzouzi, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name

      

    Title

      

    Date

    /s/ Natalie Holles

    Natalie Holles

      

    Chief Executive Officer, President and Director

    Principal Executive Officer

       May 19, 2026

    /s/ Anthony Gibney

    Anthony Gibney

      

    Chief Financial and Business Officer

    Principal Financial Officer

       May 19, 2026

    /s/ Amy Elazzouzi

    Amy Elazzouzi

      

    Senior Vice President, Finance

    Principal Accounting Officer

       May 19, 2026

    /s/ Teresa Bitetti

    Teresa Bitetti

       Director    May 19, 2026

    /s/ David Johnson

    David Johnson

       Director    May 19, 2026

    /s/ Giovanni Mariggi

    Giovanni Mariggi, Ph.D.

       Director    May 19, 2026

    /s/ Antony Mattessich

    Antony Mattessich

       Director    May 19, 2026

    /s/ Sapna Srivastava

    Sapna Srivastava, Ph.D.

       Director    May 19, 2026

    /s/ Karan Takhar

    Karan Takhar

       Director    May 19, 2026
    Get the next $AURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA

    DatePrice TargetRatingAnalyst
    11/26/2025$13.00Outperform
    Evercore ISI
    5/28/2025$22.00Buy
    H.C. Wainwright
    7/25/2024$21.00Buy
    H.C. Wainwright
    7/27/2023Sector Outperform
    Scotiabank
    4/17/2023$38.00Buy
    BTIG Research
    7/19/2022$26.00Mkt Outperform
    JMP Securities
    11/24/2021$40.00Outperform
    SVB Leerink
    11/23/2021$38.00Buy
    BTIG Research
    More analyst ratings

    $AURA
    SEC Filings

    View All

    SEC Form S-8 filed by Aura Biosciences Inc.

    S-8 - Aura Biosciences, Inc. (0001501796) (Filer)

    5/19/26 4:31:20 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Aura Biosciences Inc.

    SCHEDULE 13G - Aura Biosciences, Inc. (0001501796) (Subject)

    5/12/26 6:06:50 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Aura Biosciences Inc.

    10-Q - Aura Biosciences, Inc. (0001501796) (Filer)

    5/11/26 4:15:39 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Holles Natalie C. was granted 1,153,962 shares (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/19/26 4:59:48 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Matrix Capital Management Company, Lp sold $39,044,987 worth of shares (6,922,870 units at $5.64) (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/11/26 4:16:00 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Holles Natalie C.

    3 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/7/26 4:06:34 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Aura Biosciences with a new price target

    Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00

    11/26/25 8:36:10 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Aura Biosciences with a new price target

    H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00

    5/28/25 9:07:05 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aura Biosciences with a new price target

    H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00

    7/25/24 6:16:56 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Michael bought $98,000 worth of shares (20,000 units at $4.90), increasing direct ownership by 14% to 166,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:43:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S bought $245,000 worth of shares (50,000 units at $4.90) and sold $7,823 worth of shares (1,519 units at $5.15), increasing direct ownership by 574% to 56,933 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:34:24 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Michael bought $1,434,987 worth of shares (199,601 units at $7.19), increasing direct ownership by 171% to 135,667 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    11/9/23 5:02:28 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

    Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027. "Completing enrollment in our Pha

    6/1/26 8:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA) ("Aura" or the "Company"), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, "Inducement Awards") were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the "Grant Date"). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards consist of (i) non-qualified stock

    5/19/26 4:50:52 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences to Participate in Upcoming Investor Conferences

    BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026. Fireside Chat at 12:00 p.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026. Fireside Chat at 1:30 p.m. ET The live webcasts of the fireside chats will be available on the "Investors & Media" page under the "Events &

    5/12/26 4:01:00 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/12/24 9:32:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Leadership Updates

    Live Leadership Updates

    View All

    Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

    Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succe

    5/4/26 6:01:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

    BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit

    4/2/25 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care